TP53 Allele Burden Sharpens Risk in Diffuse Large B‑Cell Lymphoma
Variant allele frequency of TP53 mutations in diffuse large B‑cell lymphoma predicts poorer progression‑free and overall survival and may guide treatment decisions, including the use of ibrutinib plus R‑CHOP.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report